The long-term future of Britain’s CBD sector ‘really will lie with EU authorisations’, the chair of the Food Standards Agency (FSA) has told its board, a candid admission that the domestic regime the industry has chased for six years may ultimately be superseded by Brussels.
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Food Standards Agency (FSA) have both issued regulatory updates on CBD this week.
Canada’s health regulator has announced plans to establish a regulatory framework enabling CBD products to be sold over the counter without a prescription.
In a long-awaited and major step forward for the UK’s CBD sector, the regulator has announced a new roadmap that could see the first products given official approval by Spring next year.
